Amgen is no stranger to the heavy lifting required to get a new treatment for cardiovascular diseases off the ground, since its LDL cholesterol-lowering PCSK9 inhibitor Repatha (evolocumab) was not an immediate blockbuster. But now that the drug is annualizing at more than $2bn in sales, the company will use the commercialization muscles it developed for Repatha to build its strategies for Lipoprotein(a)-reducing olpasiran and obesity candidate maridebart cafraglutide (MariTide, formerly AMG 133).
Key Takeaways
- Amgen’s experience with PCSK9 inhibitor Repatha’s development as an LDL cholesterol-lowering treatment has informed the company’s planned cardiovascular disease growth strategy.
- The...
CEO Robert Bradway highlighted Repatha, olpasiran and MariTide during his J.P. Morgan Healthcare Conference presentation on 13 January and Amgen executives discussed the company’s strategy for the product and new...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?